What is Lucid Diagnostics's D&A?

Lucid Diagnostics (LUCD) reported D&A of $105K in Q1 2026.

How has Lucid Diagnostics's D&A changed year-over-year?

Lucid Diagnostics's D&A decreased by 0.0% year-over-year, from $105K to $105K.

What is the long-term trend for Lucid Diagnostics's D&A?

Over 3 years (2022 to 2025), Lucid Diagnostics's D&A has grown at a -36.6% compound annual growth rate (CAGR), from $1.65M to $420K.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Lucid Diagnostics LUCD D&A

D&A at other companies

Castle BiosciencesCSTL

$2.23M-92.1%

Fulgent Genetics, Inc.FLGT

$2.03M+2.1%

Quest DiagnosticsDGX

$37M-5.1%

Labcorp HoldingsLH

$75.6M+8.6%

GRAIL, Inc.GRAL

$33.47M0.0%

Opko HealthOPK

$18.97M-4.5%

Other financials

Income statement

See full

Revenue$1.3M+51.7%

Gross profit-$369.0K+49.0%

Operating income-$12.1M+3.0%

Net income-$13.9M+48.3%

EPS (diluted)-$0.10+60.0%

Balance sheet

See full

Cash & equivalents$27.9M+10.6%

Total debt$1.6M-35.1%

Total equity$4.0M+174%

Total assets$34.1M+3.9%

Cash flow

See full

Operating cash flow-$12.1M+2.9%

CapEx$215.0K+131%

Free cash flow-$12.3M+1.9%

Valuation

See full

Market cap$204.13M+58.5%

Enterprise value$177.85M+78.0%

P/S39.8×+10.2×

Profitability

See full

Gross margin-66.8%—

Operating margin-959.6%-133pp

Net margin-876.7%-254pp

FCF margin-1,099.6%—

Returns & leverage

See full

Return on equity-710.6%—

Debt / equity0.4×—

Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lucid Diagnostics's D&A?: Lucid Diagnostics (LUCD) reported D&A of $105K in Q1 2026.
How has Lucid Diagnostics's D&A changed year-over-year?: Lucid Diagnostics's D&A decreased by 0.0% year-over-year, from $105K to $105K.
What is the long-term trend for Lucid Diagnostics's D&A?: Over 3 years (2022 to 2025), Lucid Diagnostics's D&A has grown at a -36.6% compound annual growth rate (CAGR), from $1.65M to $420K.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.